18F-labeled, PSMA-targeted radiotracers: Leveraging the advantages of radiofluorination for prostate cancer molecular imaging

Rudolf A. Werner, Thorsten Derlin, Constantin Lapa, Sara Sheikbahaei, Takahiro Higuchi, Frederik L. Giesel, Spencer Behr, Alexander Drzezga, Hiroyuki Kimura, Andreas K. Buck, Frank M. Bengel, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe

Research output: Contribution to journalReview article

Abstract

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from 68Ga- to 18F-labeled PSMA-targeted compounds. The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68Ge/68Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, 18F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, 18F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging 18F-labeled PSMA-targeted radiotracers undergoing active clinical development. Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalTheranostics
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 1 2020

Fingerprint

Molecular Imaging
Prostatic Neoplasms
Electrons
Cyclotrons
Radiopharmaceuticals
Cost Savings
Population Density
Half-Life
human glutamate carboxypeptidase II

Keywords

  • 18F
  • 68Ga
  • PET
  • Prostate cancer
  • Prostate-specific membrane antigen
  • PSMA
  • Radiofluorine
  • Radioligand therapy
  • Theranostics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

18F-labeled, PSMA-targeted radiotracers : Leveraging the advantages of radiofluorination for prostate cancer molecular imaging. / Werner, Rudolf A.; Derlin, Thorsten; Lapa, Constantin; Sheikbahaei, Sara; Higuchi, Takahiro; Giesel, Frederik L.; Behr, Spencer; Drzezga, Alexander; Kimura, Hiroyuki; Buck, Andreas K.; Bengel, Frank M.; Pomper, Martin G.; Gorin, Michael A.; Rowe, Steven P.

In: Theranostics, Vol. 10, No. 1, 01.01.2020, p. 1-16.

Research output: Contribution to journalReview article

Werner, RA, Derlin, T, Lapa, C, Sheikbahaei, S, Higuchi, T, Giesel, FL, Behr, S, Drzezga, A, Kimura, H, Buck, AK, Bengel, FM, Pomper, MG, Gorin, MA & Rowe, SP 2020, '18F-labeled, PSMA-targeted radiotracers: Leveraging the advantages of radiofluorination for prostate cancer molecular imaging', Theranostics, vol. 10, no. 1, pp. 1-16. https://doi.org/10.7150/thno.37894
Werner, Rudolf A. ; Derlin, Thorsten ; Lapa, Constantin ; Sheikbahaei, Sara ; Higuchi, Takahiro ; Giesel, Frederik L. ; Behr, Spencer ; Drzezga, Alexander ; Kimura, Hiroyuki ; Buck, Andreas K. ; Bengel, Frank M. ; Pomper, Martin G. ; Gorin, Michael A. ; Rowe, Steven P. / 18F-labeled, PSMA-targeted radiotracers : Leveraging the advantages of radiofluorination for prostate cancer molecular imaging. In: Theranostics. 2020 ; Vol. 10, No. 1. pp. 1-16.
@article{e5c01fdb626b455a89f35f27e83678c8,
title = "18F-labeled, PSMA-targeted radiotracers: Leveraging the advantages of radiofluorination for prostate cancer molecular imaging",
abstract = "Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from 68Ga- to 18F-labeled PSMA-targeted compounds. The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68Ge/68Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, 18F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, 18F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging 18F-labeled PSMA-targeted radiotracers undergoing active clinical development. Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.",
keywords = "18F, 68Ga, PET, Prostate cancer, Prostate-specific membrane antigen, PSMA, Radiofluorine, Radioligand therapy, Theranostics",
author = "Werner, {Rudolf A.} and Thorsten Derlin and Constantin Lapa and Sara Sheikbahaei and Takahiro Higuchi and Giesel, {Frederik L.} and Spencer Behr and Alexander Drzezga and Hiroyuki Kimura and Buck, {Andreas K.} and Bengel, {Frank M.} and Pomper, {Martin G.} and Gorin, {Michael A.} and Rowe, {Steven P.}",
year = "2020",
month = "1",
day = "1",
doi = "10.7150/thno.37894",
language = "English",
volume = "10",
pages = "1--16",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "1",

}

TY - JOUR

T1 - 18F-labeled, PSMA-targeted radiotracers

T2 - Leveraging the advantages of radiofluorination for prostate cancer molecular imaging

AU - Werner, Rudolf A.

AU - Derlin, Thorsten

AU - Lapa, Constantin

AU - Sheikbahaei, Sara

AU - Higuchi, Takahiro

AU - Giesel, Frederik L.

AU - Behr, Spencer

AU - Drzezga, Alexander

AU - Kimura, Hiroyuki

AU - Buck, Andreas K.

AU - Bengel, Frank M.

AU - Pomper, Martin G.

AU - Gorin, Michael A.

AU - Rowe, Steven P.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from 68Ga- to 18F-labeled PSMA-targeted compounds. The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68Ge/68Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, 18F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, 18F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging 18F-labeled PSMA-targeted radiotracers undergoing active clinical development. Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.

AB - Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with 68Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from 68Ga- to 18F-labeled PSMA-targeted compounds. The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite 68Ge/68Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, 18F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, 18F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging 18F-labeled PSMA-targeted radiotracers undergoing active clinical development. Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available 18F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.

KW - 18F

KW - 68Ga

KW - PET

KW - Prostate cancer

KW - Prostate-specific membrane antigen

KW - PSMA

KW - Radiofluorine

KW - Radioligand therapy

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85077480142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077480142&partnerID=8YFLogxK

U2 - 10.7150/thno.37894

DO - 10.7150/thno.37894

M3 - Review article

C2 - 31903102

AN - SCOPUS:85077480142

VL - 10

SP - 1

EP - 16

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 1

ER -